Rett Syndrome from Bench to Bedside: Recent Advances
Overview
Science
Affiliations
Rett Syndrome is a severe neurological disorder mainly due to mutations in the methyl-CpG-binding protein 2 gene ( ). Mecp2 is known to play a role in chromatin organization and transcriptional regulation. In this review, we report the latest advances on the molecular function of Mecp2 and the new animal and cellular models developed to better study Rett syndrome. Finally, we present the latest innovative therapeutic approaches, ranging from classical pharmacology to correct symptoms to more innovative approaches intended to cure the pathology.
Goncalez J, Shen J, Li W Cells. 2025; 13(24.
PMID: 39768168 PMC: 11674639. DOI: 10.3390/cells13242077.
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.
Malar D, Thitilertdecha P, Ruckvongacheep K, Brimson S, Tencomnao T, Brimson J CNS Drugs. 2023; 37(5):399-440.
PMID: 37166702 PMC: 10173947. DOI: 10.1007/s40263-023-01007-6.
Li H, Hu M, Huang Z, Wang Y, Xu Y, Deng J Front Immunol. 2023; 13:1056447.
PMID: 36703978 PMC: 9871622. DOI: 10.3389/fimmu.2022.1056447.
Ren B, Dunaevsky A Int J Mol Sci. 2021; 22(4).
PMID: 33567562 PMC: 7915337. DOI: 10.3390/ijms22041692.
Multisite Study of Evoked Potentials in Rett Syndrome.
Saby J, Benke T, Peters S, Standridge S, Matsuzaki J, Cutri-French C Ann Neurol. 2021; 89(4):790-802.
PMID: 33480039 PMC: 8882338. DOI: 10.1002/ana.26029.